Prague 2025 Consensus: New Reporting Standards for AI-Driven Diagnostic Performance
What the Researchers Tested
The 'Prague 2025 consensus checklist' specifically targets the reporting of 'indirect outcome studies of Model 1b analytical performance specifications.' Model 1b APS, as defined by the Milan criteria, focuses on quantifying the effect of a diagnostic test's analytical performance on subsequent clinical classifications or decisions, acting as an intermediary to actual patient health outcomes. This is distinct from direct outcome studies, which measure patient morbidity or mortality directly. The need for this consensus arose from a lack of standardized guidance in developing such studies. An interactive workshop, followed by several expert online meetings, facilitated the development of this checklist. The process involved identifying key methodological challenges and limitations inherent in Model 1b APS studies. The resulting checklist contains 17 core reporting items, complemented by explanatory notes. A significant architectural feature is its cross-referencing to 25 items from the 2025 STARD-AI guidelines, indicating a deliberate effort to align conventional diagnostic performance standards with emerging AI validation requirements. This synergistic approach aims to ensure that analytical performance claims, particularly those underpinning AI-driven diagnostics, are rigorously reported and scientifically sound.
What the Study Found
The Prague 2025 consensus introduces a 17-item checklist for reporting indirect outcome studies of Model 1b Analytical Performance Specifications (APS).
Model 1b APS assesses the impact of analytical test performance on clinical classifications and decisions, serving as an indirect measure of patient health outcomes.
The checklist cross-references 25 items from the 2025 STAndards for Reporting Diagnostic accuracy studies using Artificial Intelligence (STARD-AI), signifying a harmonization of traditional and AI-specific reporting standards.
The initiative aims to provide generic methodological standards for the design, conduct, and reporting of Model 1b APS studies, ensuring scientific validity, robustness, and transferability across healthcare settings.
Development involved an interactive expert workshop and online meetings to address key challenges and limitations in current Model 1b APS study methodologies.
Why This Matters to Clinical Practice
For practicing clinicians, department heads, and hospital leadership, this consensus is paramount for several reasons. The proliferation of AI in diagnostics necessitates clear, standardized reporting to accurately interpret the clinical utility and reliability of new tests. Without such guidelines, evaluating the true impact of AI-augmented diagnostic tools on patient management and outcomes becomes challenging, potentially leading to misinformed clinical decisions or under-utilization of effective technologies. Robust Model 1b APS reporting, guided by the Prague 2025 checklist, will enhance confidence in AI-driven diagnostics by ensuring that the analytical performance specifications are well-defined, validated, and transparently communicated. This directly impacts patient safety and the efficiency of care pathways. By standardizing the reporting of indirect outcomes, healthcare systems can better assess the value of new diagnostic AI tools, streamline their adoption, and ultimately improve the quality and consistency of patient care by mitigating risks associated with inadequately validated analytical performance.
Clinical & Workflow Takeaways
Clinicians and clinical department heads should familiarize themselves with the principles of the Prague 2025 consensus, particularly when evaluating diagnostic tests that claim AI-enhanced analytical performance. When reviewing vendor data or research publications on new diagnostic AI tools, prioritize studies that explicitly adhere to or reference these reporting standards. Laboratory directors should integrate these guidelines into their evaluation protocols for new assays, focusing on how analytical variations impact clinical decision-making. For researchers developing AI-driven diagnostics, strict adherence to this checklist and the STARD-AI guidelines is crucial for generating high-quality, publishable, and clinically trustworthy evidence. Hospital leadership should consider advocating for the adoption of these reporting standards within their procurement processes for AI-enabled diagnostic platforms to ensure robust evidence of clinical utility and safety.
Limitations and What Remains Uncertain
While highly beneficial, the Prague 2025 consensus and its checklist primarily focus on indirect outcome studies, meaning they evaluate the impact on clinical decisions or classifications rather than direct patient health outcomes such as morbidity or mortality. This indirect nature necessitates further studies to confirm the downstream benefits at the patient level. The effectiveness of the checklist relies on broad adoption by researchers, journals, and regulatory bodies, which may take time. The inherent complexity of harmonizing traditional analytical performance criteria with AI-specific validation (STARD-AI) could present challenges in implementation, particularly for smaller research groups or institutions with limited resources. Furthermore, the checklist's 'generic methodological standards' will still require careful adaptation to the unique characteristics of diverse diagnostic tests and AI algorithms.
Explore the Work Behind Clinical AI
MedXchange Research Fellowship
Publish Clinical AI Research With Us
Our 10-week fellowship mentors physicians and researchers to build foundation models, analyze multimodal health datasets, and co-author peer-reviewed clinical studies.
Related Clinical AI Stories
FDA Digital Health Update: Guidance on Lifecycle Management for Adaptive Generative AI Devices
The US Food and Drug Administration (FDA) Digital Health Center of Excellence published revised draft guidance establishing rigorous Pre-Determined Change Control Plans (PCCPs) for generative AI and continuously learning machine learning algorithms in clinical decision support software (SaMD).
FDA Issues Expanded Final Guidance on Lifecycle Management for Adaptive Generative AI Diagnostics
The US Food and Drug Administration (FDA) Digital Health Center of Excellence has released an expanded final guidance framework detailing regulatory clearance pathways for adaptive generative AI and multi-agent clinical decision support systems. Departing from static 'locked-box' algorithm clearances, the new guidance establishes formal Predetermined Change Control Plans (PCCPs) that permit continuous learning models to update weights based on localized hospital EHR data. The regulatory update is hailed by health informatics leaders as the most consequential modernization of medical device oversight in over a decade, establishing clear safety guardrails for ambient clinical copilots and autonomous diagnostic triage systems.
FDA Grants De Novo Authorization for Autonomous Point-of-Care Handheld Cardiac Ultrasound AI
The US Food and Drug Administration (FDA) has granted De Novo regulatory clearance for an autonomous point-of-care ultrasound (POCUS) artificial intelligence system, reported by Bloomberg Health AI. The clearance authorizes non-specialist clinical personnelâincluding registered nurses, paramedics, and triage medical assistantsâto acquire diagnostic-quality transthoracic echocardiography views guided by real-time spatial AI navigation. The landmark regulatory decision is expected to democratize bedside cardiac assessment across emergency rooms, rural clinics, and ambulatory heart failure management programs.